Develops, manufactures and markets a line of innovative, technologically enhanced PVC-free and latex-free urinary continence and urine drainage care products for the extended care and acute care markets.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
While current p/e of 4 reflects big judgment against rivals, a rudimentary analysis that spreads the judgment over the years (assuming it was earned from sales) gives a p/e of 6, which is still darn good; three of the competitors acceded, 4th one, Covidian isnt a big player, so the money from that settlement unlikely to be big; one of the rivals had to agree marketing company products; this bodes well because it has other innovations in addition to the litigated catheters; the court win shows the grit and determination of the company, like David slaying the Goliaths; stock beaten down by Investors Business Daily speculators taking losses for 07; still ignored by herding Wall Street analysts; while insiders have been selling, it was at higher levels and they still have very high equity in the company; $150 mil foley catheters sell per year, almost ROCM's market cap, company may be able to charge more for its premium product.
egenessisDo not be mislead by the low P/E. The forward P/E is more useful. Current P/E is based on a large legal settlement in the last year which should be considered as a one time event (though there are other legal proceedings ongoing). Back it out of revenues and you have a P/E in the 30's. Now that is OK in my opinion based on growth expectations and opportunities.See my pitch and blog for some more commentary on reasons to be bullish on this company.HelicalZz